<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4645289</article-id><article-id pub-id-type="publisher-id">2051-1426-3-S2-P145</article-id><article-id pub-id-type="doi">10.1186/2051-1426-3-S2-P145</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Drake</surname><given-names>Charles G</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Quinn</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Dreicer</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Antonarakis</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Shore</surname><given-names>Neal</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Corman</surname><given-names>John</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Concepcion</surname><given-names>Raoul</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Pieczonka</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Campogan</surname><given-names>Dwayne</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Fan</surname><given-names>Li-Qun</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" corresp="yes" id="A11"><name><surname>Chang</surname><given-names>Nancy</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Sheikh</surname><given-names>Nadeem</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Petrylak</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA</aff><aff id="I2"><label>2</label>Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA</aff><aff id="I3"><label>3</label>University of Virginia Cancer Center, Charlottesville, VA, USA</aff><aff id="I4"><label>4</label>Johns Hopkins University School of Medicine, Baltimore, MD, USA</aff><aff id="I5"><label>5</label>Atlantic Urology Clinics, Myrtle Beach, SC, USA</aff><aff id="I6"><label>6</label>Virginia Mason Cancer Institute, Seattle, WA, USA</aff><aff id="I7"><label>7</label>Urology Associates, Nashville, TN, USA</aff><aff id="I8"><label>8</label>Associated Medical Professionals of New York, Syracuse, NY, USA</aff><aff id="I9"><label>9</label>Dendreon, Seattle, WA, USA</aff><aff id="I10"><label>10</label>Yale Cancer Center, New Haven, CT, USA</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>4</day><month>11</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by SITC 2015.</named-content></supplement><fpage>P145</fpage><lpage>P145</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Drake et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Drake et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/3/S2/P145"/><conference><conf-date>4-8 November 2015</conf-date><conf-name>30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</conf-name><conf-loc>National Harbor, MD, USA</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>P12-2 (STRIDE; NCT01981122) is an ongoing, randomized, Phase II, open-label study evaluating concurrent vs sequential administration of the androgen receptor inhibitor, enz, with the autologous cellular immunotherapy, sip-T. The primary aim of this study is to determine if the order of sip-T and enz administration impacts immune responses to the immunizing antigen, PA2024, of sip-T.</p></sec><sec><title>Methods</title><p>Patients with asymptomatic or minimally symptomatic mCRPC were randomized 1:1 to receive 3 sip-T infusions with enz starting 2 weeks (wks) before (n=25, concurrent arm A) or 10 wks after (n=27, sequential arm B) sip-T initiation. Antigen-specific cellular and humoral immune responses were evaluated via interferon (IFN)-&#x003b3; ELISPOT, cell proliferation, and antibody ELISA assays. In addition, the breadth of the humoral response to non-target antigens was also studied.</p></sec><sec><title>Results</title><p>T cell proliferative responses to PA2024 were significantly elevated at all post-baseline time points (p &#x0003c; 0.001) and were sustained through wk 26, including a &#x0003e;10-fold increase at wk 20 in both arms. Both arms showed a significant and sustained increase in IFN-&#x003b3; ELISPOT response to PA2024 and humoral responses to PA2024 and PAP. Broadening of the humoral responses to non-target antigens PSA, LGALS3, LGALS8, KRAS, ERAS and KLK2 at all post-treatment time points was observed in both arms. Cytokines indicative of immune activation (including IFN-&#x003b3;, interleukin-2, and tumor necrosis factor-&#x003b1;) were also elevated in both arms, at the 2<sup>nd</sup> and 3<sup>rd</sup> sip-T infusions. Adverse events were similar between arms.</p></sec><sec><title>Conclusions</title><p>Treatment of mCRPC subjects with enz administered concurrently with or subsequent to sip-T resulted in significant and sustained peripheral antigen-specific T cell and humoral immune responses through wk 26. Both treatment schedules led to similarly robust humoral antigen spread sustained through wk 26. These data suggest enz did not affect sip-T production, subsequent immune responses, or safety.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov identifier NCT01981122.</p></sec></body></article>